Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cannabix Technologies Inc. (BLO) has announced that the Canadian Intellectual Property Office has approved the company’s patent application
  • The company has been pursuing the patent application since originally filing for approval on April 16, 2015
  • Cannabix Technologies also said that in June it delivered its THC Breath Analyzer to a Northwestern United States clinic for beta testing
  • The beta testing will focus on improving user and administrator experience that will be able to identify cross-reactivity of other substances 
  • Shares of Cannabix Technologies are up 25.49 per cent to C$1.28 as of 11:32 a.m. EDT

Cannabix Technologies (BLO) has received approval from the Canadian Intellectual Property Office for its “Cannabis Drug Detection Device” patent application.

The company initially filed for its patent application back on April 16, 2015. 

“Similar to our USPTO patent, the intellectual property protection this THC detection patent covers, gives Cannabix a broad foundation to build upon in view of the formidable insights and technical advancements made in the field of molecular gas analysis at atmospheric pressure that we have developed since this patent was initially filed in 2015. This patent is a useful plank in our IP protection strategy,” Dr. Raj Attariwala said in a press release.

Cannabix Technologies also reported that its THC Breath Analyzer has been delivered to a Northwestern U.S. clinic for beta testing., which has a drug testing operation and is a top drug testing provider in its state.

The beta testing will focus on improving user and administer experience and will help identify cross-reactivity of other substances in a semi-controlled study population. The testing will also help further train the device’s learning database and sensitivity profile.

“There is a massive sea-change happening in the U.S. related to cannabis use and Cannabix Technologies is at the forefront of developing the tools to aid public safety and create more relevant and fairer cannabis testing technology,” Cannabix Technologies’ CEO Rav Mlait said in a release.

With its headquarters in Vancouver, BC, Cannabix Technologies develops marijuana breathalyzer technologies for both law enforcement and the workplace. The company is focused on developing drug-testing devices that screen for THC, which is the component of marijuana that indicates impairment using breath samples. 

Shares of Cannabix Technologies are up 25.49 per cent to C$1.28 as of 11:32 a.m. EDT.

More From The Market Herald

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.

" West Island Brands (CSE:WIB) releases Q1 financial results

West Island Brands (WIB) has released unaudited first quarter 2022 financial results.

" Sweet Earth (CSE:SE) signs LOI to acquire strategic targets from ST Group

Sweet Earth Holdings (SE) has signed an LOI with ST Group to explore the amalgamation of certain partner assets and companies into Sweet

" Vibe Growth (CSE:VIBE) obtains approval for greenhouse cultivation license

Vibe Growth (VIBE) has been granted a commercial cannabis cultivation license by the State of California’s Department of Cannabis Control.